Biotechnology — GM Crops, CRISPR, Regulatory Framework, Bioeconomy & India's Biotech Sector

Biotechnology — Overview

Biotechnology is the use of living organisms, cells, or biological systems to develop products and technologies for human benefit. It spans agriculture, health, industry, and environment.

Colour Classification of Biotechnology

India's Bioeconomy & BioE3 Policy

India's Bioeconomy Growth

BioE3 Policy (2024)

BioE3 significance: Aligns with India's Net Zero and LiFE goals. Promotes circular bioeconomy and green growth, with job creation in tier-II/III cities through biomanufacturing hubs.

Genetic Engineering — Key Concepts

Prelims Trap: GMOs and genome-edited organisms are NOT the same. GMOs contain foreign DNA (transgenic). Genome-edited organisms have their own DNA modified — no foreign genetic material is introduced. India's 2022 guidelines treat genome-edited plants (SDN-1 and SDN-2 categories) differently from GMOs, with a lighter regulatory pathway.

CRISPR-Cas9

How It Works

CRISPR Applications

India's CRISPR institutions: National Centre for Genome Editing & Training (NGETC) at Mohali; regulatory framework under National Guidelines for Gene Therapy (2019), CDSCO, NDCT Rules 2019.

GM Crops in India

Bt Cotton — India's Only Approved GM Crop

For Mains: The Bt cotton story is nuanced. Initial benefits were real — tripled yields, ~70% reduction in pesticide use against bollworm. But pink bollworm resistance development and dependence on proprietary seeds created new vulnerabilities. Use as a case study of technology adoption — benefits vs risks of monoculture and corporate dependency.

Bt Brinjal — Moratorium Since 2010

GM Mustard (DMH-11) — Ongoing Controversy

Why it matters: DMH-11 could be India's second GM crop after 22 years. The debate combines science (safety), politics (anti-GM activism), economics (edible oil import burden), and federalism (states like Rajasthan oppose). A classic multi-dimensional Mains question.

Genome-Edited Crops — India's New Pathway (2025)

India approved its first genome-edited crop varieties in 2025 — NOT GMOs (no foreign DNA; SDN-1 category edit):

India's 2022 genome editing guidelines exempt SDN-1 and SDN-2 edits from the full GMO regulatory process — creating a faster innovation pathway for crops that only modify the plant's own DNA.

Common Prelims Mistake: Bt Cotton is the ONLY commercially approved GM crop in India (since 2002). Bt Brinjal was approved but placed under moratorium (2010). GM Mustard got GEAC approval (2022) but is in legal limbo (SC 2024). Genome-edited crops (Pusa Rice DST1, DRR Dhan 100) are NOT GMOs — different regulatory category.

Regulatory Framework for GMOs in India

Key Laws

International: Cartagena Protocol on Biosafety

India's Rules 1989 under EPA 1986 are broadly aligned with the Cartagena Protocol's requirements for risk assessment and information exchange.

Key Biosafety Risks

Six-Tier Regulatory Structure

Prelims Fact: GEAC (under MoEFCC) is the apex approval body. RCGM (under DBT) handles research-stage approvals. Don't confuse the two. Agriculture is a State subject, but GM crop regulation is under EPA 1986 (Union law) — creating Centre-state tension.

Genome Editing Guidelines — SDN Categories (2022)

Medical Biotechnology

Gene Therapy

Key Indian Vaccine Contributions

Genome Sequencing Projects

Why Genome India matters: Global genomic databases are dominated by European-ancestry data. Indians are genetically distinct and diverse. Without an Indian reference genome, precision medicine cannot work for India's population.

Biotech in Agriculture — Beyond GM Crops

Key Technologies

Biofortification — Key Indian Varieties

ICAR has released 71+ biofortified varieties across multiple crops:

Golden Rice (engineered with beta-carotene genes) approved in Australia, New Zealand, Canada — NOT approved in India. Remains a GM crops debate topic.

India's Biotech Institutional Framework

Department of Biotechnology (DBT)

BIRAC (Biotechnology Industry Research Assistance Council)

National Biopharma Mission (NBM/i3)

India's Biopharmaceuticals — Global Position

One Health Approach

Exam Tip: For any UPSC answer on COVID-19, AMR, or avian flu, invoke the One Health framework. Key fact: ~75% of emerging infectious diseases are zoonotic. India's NAP-AMR (2017) explicitly adopted this approach. The institutional challenge is inter-ministerial coordination between MoHFW, MoAHD, and MoEFCC.

Antimicrobial Resistance (AMR)

Ethical and Social Dimensions

Biopiracy Landmark Cases

Turmeric Patent (1995–1997):

• US Patent No. US5401504A granted to University of Mississippi Medical Centre (1995) for use of turmeric in wound healing
• CSIR challenged it, proving turmeric's wound-healing use was documented in ancient Ayurvedic texts — not novel
• USPTO revoked the patent in 1997 — one of the earliest successful biopiracy challenges

Neem Patent (1994–2005):

• European Patent Office (EPO) granted Patent EP436257 to W.R. Grace & Co. and USDA on a neem-based fungicide (1994)
• Dr. Vandana Shiva and activists filed opposition citing India's traditional neem use
• EPO revoked the patent in May 2000; appeal confirmed final revocation in 2005

Traditional Knowledge Digital Library (TKDL)

TKDL represents India's "defensive protection" strategy — documenting traditional knowledge as prior art to prevent others from patenting it, rather than patenting it (which may not meet novelty criteria).

Important for UPSC

Prelims Focus Areas

• Bt Cotton: only GM crop approved in India (2002); GEAC is apex body under MoEFCC (not MoA or DBT)
• Bt Brinjal moratorium: February 2010, Jairam Ramesh; moratorium continues
• GM Mustard (DMH-11): GEAC approved October 2022; SC split verdict 2024; legal limbo
• Genome-edited crops (2025): Pusa Rice DST1 + DRR Dhan 100 — NOT GMOs (SDN-1 category)
• CRISPR: Nobel Prize Chemistry 2020 — Doudna & Charpentier; FELUDA = Tata + CSIR-IGIB
• SDN-1/SDN-2/SDN-3 categories for genome editing
• DBT established 1986; BIRAC = PSE under DBT
• BioE3 Policy: Cabinet August 24, 2024; $195.3B bioeconomy (2025)
• NAP-AMR launched 2017; updated 2024; ESKAPE pathogens
• GenomeIndia: 10,074 individuals, 83 populations; IndiGen: 1,029 individuals
• Biofortified varieties: Pusa Tejas (wheat), Dhanashakti (pearl millet), CR Dhan 315 (rice)
• BIRSA 101: India's first indigenous CRISPR gene therapy (CSIR-IGIB + SII)

Mains Dimensions

Interview Angles

• Should India allow GM food crops beyond Bt Cotton? What's the right balance between food security and biosafety?
• Gene editing: where should India draw the ethical line? Crops vs animals vs human germline?
• India's TKDL model — can traditional knowledge be effectively protected in the IP regime?
• Is India's bioeconomy growth ($195B) benefiting small farmers and rural populations?
• One Health: is India's institutional structure adequate for cross-sectoral health governance?

Recent Developments (2024–2026)

BioE3 Policy — India's Biomanufacturing Strategy (August 2024)

The Union Cabinet approved the BioE3 (Biotechnology for Economy, Environment, and Employment) Policy in August 2024, implemented by the Department of Biotechnology (DBT). The policy identifies six strategic sectors for high-performance biomanufacturing: (a) bio-based chemicals and enzymes, (b) functional foods and smart proteins, (c) precision biotherapeutics (gene therapy, mRNA, cell therapy), (d) climate-resilient agriculture, (e) carbon capture and utilisation, and (f) marine and space biotech.

BioE3 positions India to become a global biomanufacturing hub alongside the USA's National Biotechnology and Biomanufacturing Initiative (2022) and the EU's Green Deal bioeconomy strategy. India's bioeconomy reached approximately $130 billion in 2024 — the government targets $300 billion by 2030. BioE3's precision biotherapeutics vertical includes gene therapies for haematological diseases (Hemophilia A, Thalassaemia) and mRNA therapeutics — directly supported by DBT's clinical trial funding.

UPSC angle: BioE3 Policy, DBT role, six strategic sectors, India's bioeconomy target ($300 billion by 2030), and gene therapy pipeline are Mains GS-3 content.

India's BIRSA 101 — First Indigenous CRISPR Therapy for Sickle Cell Disease (November 2025)

India launched its first indigenous CRISPR-based gene therapy for sickle cell disease — named "BIRSA 101" (a tribute to Bhagwan Birsa Munda) — in November 2025, under the Ministry of Tribal Affairs in partnership with AIIMS Delhi and IGIB (Institute of Genomics and Integrative Biology). BIRSA 101 uses the Indian-developed enFnCas9 enzyme (enhanced, patented by IGIB) for precision editing of the beta-globin gene.

This makes India one of the few countries globally with an indigenous CRISPR therapy in clinical use. The Casgevy therapy (by Vertex Pharmaceuticals and CRISPR Therapeutics), approved in the UK (2023) and USA (2023), costs over $2.2 million per patient — making it inaccessible for India's estimated 30 million sickle cell carriers. BIRSA 101's domestic development aims to make curative therapy affordable.

UPSC angle: BIRSA 101, sickle cell disease burden in India (Tribal population particularly affected), IGIB's enFnCas9, and affordable gene therapy as a public health goal are Mains GS-3/GS-2 content.

GM Crops — Mustard DBH-11 and Regulatory Updates 2024

India's only commercially approved GM crop remains Bt cotton (since 2002). In 2024, the Genetic Engineering Appraisal Committee (GEAC) continued its review of GM Mustard (DMH-11, developed by Delhi University). The Supreme Court had directed the government to disclose the complete regulatory file, and the issue remained in litigation with environmental groups challenging the herbicide-tolerance aspect of DMH-11.

The broader GMO regulatory debate gained urgency as Bt Brinjal (approved in Bangladesh in 2014 and showing yield benefits) and drought-tolerant GM maize are pending Indian review. BioE3 Policy's "climate-resilient agriculture" vertical could accelerate approvals for drought/heat-tolerant crop varieties, though the food safety-environmental tradeoff debate continues.

UPSC angle: GM Mustard status (GEAC review, SC direction), India's GMO regulatory framework (GEAC, RCGM, IBSC), and the DMH-11 herbicide tolerance controversy are Prelims and Mains content.

Vocabulary

Genome

• Pronunciation: /ˈdʒiː.nəʊm/
• Definition: The complete set of genetic material (DNA or, in some viruses, RNA) present in a cell or organism, containing all the information needed for that organism's development and function.
• Origin: Coined by German botanist Hans Winkler in 1920, as a blend of German Gen ("gene") and Chromosom ("chromosome").

CRISPR

• Pronunciation: /ˈkrɪs.pər/
• Definition: An acronym for Clustered Regularly Interspaced Short Palindromic Repeats, a gene-editing technology derived from a bacterial defence system that enables precise modification of DNA sequences in living organisms.
• Origin: The acronym was proposed by Francisco Mojica and Ruud Jansen in 2001; the gene-editing application using CRISPR-Cas9 was developed by Jennifer Doudna and Emmanuelle Charpentier (Nobel Prize in Chemistry, 2020).

Transgenic

• Pronunciation: /trænzˈdʒɛn.ɪk/
• Definition: Describing an organism whose genome has been altered by the introduction of one or more genes from a different species using genetic engineering techniques.
• Origin: From Latin trans- ("across") + Greek genos ("race, kind") + -ic; coined in the 1980s to describe organisms carrying foreign genetic material.

Biopesticide

• Pronunciation: /ˌbaɪoʊˈpɛstɪˌsaɪd/
• Definition: A pest-control agent derived from natural biological sources — such as bacteria, fungi, viruses, or plant extracts — used as an environmentally safer alternative to synthetic chemical pesticides.
• Origin: Compound of Greek bios ("life") + Latin pestis ("plague, pest") + -cide (from Latin caedere, "to kill").

Biofertiliser

• Pronunciation: /ˌbaɪoʊˈfɜːrtɪˌlaɪzər/
• Definition: A substance containing living micro-organisms — such as nitrogen-fixing bacteria (Rhizobium) or phosphate-solubilising fungi — that, when applied to seeds, plant surfaces, or soil, enhances nutrient availability and promotes plant growth.
• Origin: Contraction of biological fertiliser; bio- from Greek bios ("life").

Key Terms

Genetic Modification

• Pronunciation: /dʒəˈnɛt.ɪk ˌmɒd.ɪ.fɪˈkeɪ.ʃən/
• Definition: The deliberate alteration of an organism's DNA using laboratory techniques — including insertion of foreign genes (transgenic), deletion of existing genes, or site-specific modification using CRISPR-Cas9. The key regulatory distinction: traditional GM (foreign DNA, full GEAC process) vs genome editing SDN-1/SDN-2 (no foreign DNA, lighter regulation).
• Context: Bt cotton (cry1Ac gene) is India's only approved GM crop since 2002. Bt Brinjal was approved by GEAC October 2009 but placed under moratorium February 2010 (Jairam Ramesh). GM Mustard (DMH-11) received GEAC approval October 2022 but faces SC legal challenge (split verdict 2024). India's first genome-edited crops (Pusa Rice DST1, DRR Dhan 100) approved 2025 — SDN-1 category, no foreign DNA.
• UPSC Relevance: GS3 (Science & Technology). Know SDN-1/SDN-2/SDN-3 categories; GEAC under MoEFCC is apex GM approval body; RCGM under DBT handles research stage. Mains: GM crops debate, biopiracy (TKDL, Neem/Turmeric), Centre-state tensions, food security vs biosafety.

Bt Cotton

• Pronunciation: /ˌbiː ˈtiː ˈkɒtən/
• Definition: India's only approved GM crop (since 2002), containing the cry1Ac gene from Bacillus thuringiensis that produces insecticidal proteins toxic to bollworm larvae. Covers ~95% of India's cotton area; tripled cotton production by 2014. Controversies: pink bollworm resistance emerged; seed monopoly concerns (Monsanto/Bayer); farmer suicide debate (correlation only, not proven causation).
• UPSC Relevance: GS3. Prelims: approved 2002, only approved GM crop, GEAC under MoEFCC. Mains: Use as case study for technology adoption — initial success (tripled production, ~70% pesticide reduction) vs emerging challenges (resistance, dependency). Centre-state regulation tensions.

GM Crops Regulation

• Pronunciation: /ˌdʒiː ˈɛm krɒps ˌrɛɡjuˈleɪʃən/
• Definition: India's six-tier framework: IBSC (institution) → RCGM (DBT) → RDAC (DBT policy) → SBCC (state) → DLC (district) → GEAC (apex, MoEFCC). Primary law: GMO Rules 1989 under EPA 1986. GEAC renamed from "Approval" to "Appraisal" Committee in July 2010. SDN-1/SDN-2 genome-edited plants exempt from full GMO process per 2022 SOPs.
• UPSC Relevance: GS3 (Governance/Science). Know GEAC is under MoEFCC not DBT. Mains: Centre-state friction (agriculture = State subject; GM regulation = Union law), adequacy of India's regulatory framework, GM Mustard SC case 2024.

Stem Cell Therapy

• Pronunciation: /stɛm sɛl ˈθɛr.ə.pi/
• Definition: Regenerative medicine using stem cells to repair or replace diseased tissues. Types: embryonic stem cells (pluripotent), adult/somatic stem cells (multipotent), and induced pluripotent stem cells (iPSCs — adult cells reprogrammed by Shinya Yamanaka, Nobel 2012). India's regulatory framework: ICMR-DBT National Guidelines for Stem Cell Research (1st 2007, revised 2017). Reproductive cloning prohibited; therapeutic cloning permitted under oversight.
• UPSC Relevance: GS3. Prelims: types of stem cells; iPSC Nobel 2012 (Yamanaka + Gurdon). Mains: ethical concerns (embryonic SC research involves embryo destruction), India's regulatory framework, therapeutic applications (bone marrow transplants, potential for Parkinson's, diabetes).

Current Affairs Connect

Sources: pib.gov.in, dbtindia.gov.in, birac.nic.in, mohfw.gov.in, nhm.gov.in, nha.gov.in, moefcc.gov.in, ncdc.mohfw.gov.in, india.gov.in, Lancet 2022 (AMR data), ICAR biofortification data.